Literature DB >> 9058594

Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P.

T Sumizawa1, Z S Chen, Y Chuman, K Seto, T Furukawa, M Haraguchi, A Tani, N Shudo, S I Akiyama.   

Abstract

Three agents, verapamil, cepharanthine, and 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl-5-(trans-4,6-dimethyl-1, 3,2-dioxaphosphorinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-3-py ridinecarboxylate P-oxide (PAK-104P), that reverse drug resistance in P-glycoprotein (P-Gp)-mediated multidrug-resistant cells were examined for their activity to reverse drug resistance in multidrug resistance-associated protein (MRP)-mediated multidrug-resistant C-A120 cells. Agents other than PAK-104P could not reverse the resistance to doxorubicin in C-A120 cells. PAK-104P moderately reversed the doxorubicin resistance. In contrast, PAK-104P almost completely reversed the resistance to vincristine (VCR) in C-A120 cells as well as in KB-8-5 cells, and other agents moderately reversed the VCR resistance in C-A120 cells. PAK-104P at 10 microM enhanced the accumulation of VCR in C-A120 cells to the level of that in KB-3-1 cells without the agent. PAK-104P competitively inhibited the ATP-dependent [3H]leukotriene C4 uptake in membrane vesicles isolated from C-A120 cells. These findings demonstrate that PAK-104P can completely reverse the resistance to VCR in both P-Gp- and MRP-mediated multidrug-resistant cells and that PAK-104P directly interacts with MRP and inhibits the transporting activity of MRP.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9058594

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  5 in total

1.  BCRP transports dipyridamole and is inhibited by calcium channel blockers.

Authors:  Yi Zhang; Anshul Gupta; Honggang Wang; Lin Zhou; R Robert Vethanayagam; Jashvant D Unadkat; Qingcheng Mao
Journal:  Pharm Res       Date:  2005-11-01       Impact factor: 4.200

2.  Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).

Authors:  Tong Shen; Ye-Hong Kuang; Charles R Ashby; Yu Lei; Angel Chen; Ying Zhou; Xiang Chen; Amit K Tiwari; Elizabeth Hopper-Borge; Jiangyong Ouyang; Zhe-Sheng Chen
Journal:  PLoS One       Date:  2009-10-20       Impact factor: 3.240

3.  Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance.

Authors:  Ye-Hong Kuang; Tong Shen; Xiang Chen; Kamlesh Sodani; Elizabeth Hopper-Borge; Amit K Tiwari; Jeferson W K K Lee; Li-Wu Fu; Zhe-Sheng Chen
Journal:  Biochem Pharmacol       Date:  2009-08-29       Impact factor: 5.858

4.  Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines.

Authors:  Masanori Shimomura; Takeshi Yaoi; Kyoko Itoh; Daishiro Kato; Kunihiko Terauchi; Junichi Shimada; Shinji Fushiki
Journal:  Int J Oncol       Date:  2011-12-13       Impact factor: 5.650

5.  Reversing effect of agosterol A, a spongean sterol acetate, on multidrug resistance in human carcinoma cells.

Authors:  S Aoki; Z S Chen; K Higasiyama; A Setiawan; S Akiyama; M Kobayashi
Journal:  Jpn J Cancer Res       Date:  2001-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.